{"title":"糖蛋白IIb/IIIa抑制剂在接受冠状动脉血管重建术的急性冠状动脉综合征患者中的应用","authors":"J J Popma","doi":"10.1159/000054115","DOIUrl":null,"url":null,"abstract":"<p><p>This paper briefly reviews the results from three recent large-scale clinical trials evaluating the benefit of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes (ACS). The available data suggest that these are promising agents for the management of ACS, particularly in improving the immediate outcome in the acute setting.</p>","PeriodicalId":12910,"journal":{"name":"Haemostasis","volume":"29 Suppl S1 ","pages":"69-71"},"PeriodicalIF":0.0000,"publicationDate":"1999-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000054115","citationCount":"0","resultStr":"{\"title\":\"Use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing coronary revascularization.\",\"authors\":\"J J Popma\",\"doi\":\"10.1159/000054115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This paper briefly reviews the results from three recent large-scale clinical trials evaluating the benefit of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes (ACS). The available data suggest that these are promising agents for the management of ACS, particularly in improving the immediate outcome in the acute setting.</p>\",\"PeriodicalId\":12910,\"journal\":{\"name\":\"Haemostasis\",\"volume\":\"29 Suppl S1 \",\"pages\":\"69-71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000054115\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haemostasis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000054115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haemostasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000054115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing coronary revascularization.
This paper briefly reviews the results from three recent large-scale clinical trials evaluating the benefit of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes (ACS). The available data suggest that these are promising agents for the management of ACS, particularly in improving the immediate outcome in the acute setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
